FDA Says All Options on the Table at LDT Meeting | GenomeWeb

By Turna Ray

HYATTSVILLE, Md. (GenomeWeb Daily News) – During the first day of a two-day meeting held here this week to discuss the US Food and Drug Administration's regulatory strategy for laboratory-developed tests, agency officials said that all options are on the table and "nothing is set in stone."

However, comments from one high-ranking agency official provided a glimpse of the ideas in play with regard to its risk-based regulation of LDTs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.